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Myeloproliferative neoplasms, and lymphoid malignanciesINTRODUCTION
This is the second part of disease-specific methods
and strategies for monitoring relapse following
allogeneic hematopoietic stem cell transplantation
(alloHSCT). In the first part, we focused on disease-
specific monitoring of acute leukemias and myelodys-
plastic syndrome (MDS) [1]. Here, in this second part
we will review disease-specific monitoring for chronic
leukemias, chronic myeloproliferative neoplasms, and
lymphoid malignancies.
Methodologic and technologic advances allow sen-
sitive detection of minimal residual disease (MRD) and
early recognition of recurrence after alloHSCT. Im-
portantly, intervention prior to florid relapse improves
outcome for certain hematologic malignancies [2,3].
This manuscript by the Workshop Committee on
Disease-Specific Methods and Strategies for Monitoring
Relapse following Allogeneic Stem Cell Transplantation is
derived into 2 parts and reviews disease-specific detec-
tion methods and available data with the use of such
after alloHSCT. Given the critical importance to the
goals of this Workshop, standard disease-specific re-
sponse and relapse criteria are summarized. Outside
of the alloHSCT setting, international working groups
have developed standard diagnostic criteria that are
widely employed in the definition of relapse for the dif-
ferent hematologic malignancies [4]. These are based
primarily on morphologic investigations of peripheral
blood (PB) and/or bone marrow (BM) imaging, and/
or specific laboratory findings. After alloHSCT, more
sensitive methods such as molecular genetics, tumor-
specific molecular primers, fluorescence in situ hybrid-
ization (FISH), multiparameter flow cytometry (MFC),
and/or chimerism (see part I) are commonly used to
monitor patients with respect to relapse. Some of these
have clearly been shown to be predictive of outcome in
specific diseases (eg, chronic myelogenous leukemia
[CML]). However, the utility of the array of available
tools in the monitoring of disease status after
alloHSCT has not yet been fully elucidated across all
hematologic malignancies. It is anticipated that sensi-
tive MRD detection will allow for earlier therapeutic
intervention, and it is hoped that treatment prior to
overt relapse may improve outcome of alloHSCT for
hematologic malignancies. Critically important is the
need to assess the clinical relevance of MRD surveil-
lance in individual diseases, which in turn must befollowed by studies to assess the potential impact of
specific interventional strategies. Recommendations
for the utilization of sensitive monitoring techniques
to augment the standard definitions of posttransplant
remission, persistence, progression, and relapse, and
to predict of relapse are proposed, based on current,
available evidence whenever possible. From the point
of view of this Committee, the use of these proposed
definitions andmethods should facilitate future studies
of the natural history of relapse (Committee on Epi-
demiology and Natural History of Relapse), therapeutic
interventions to prevent clinical relapse (Committee on
Strategies/TherapiesUsed toPreventRelapse), and the treat-
ment of relapse (Ccommittee on Disease-Specific Treatment
of Relapse). Finally, major deficits and important ques-
tions for further clinical research will be addressed.METHODS TO DETECTAND MONITOR
DISEASE RESPONSE, PERSISTENCE,
PROGRESSION, AND RELAPSE
A wide variety of techniques are available to moni-
tor residual disease after therapy, including in the post-
transplant setting (Table 1), although the applicability
varies by the specific disease subtype and the predictive
value of each method is currently not well defined for
most diseases. Some of these techniques are difficult
to standardize, which is essential to the conduct of
multicenter studies to assess the utility in the prediction
and possible prevention of overt relapse.
Broadly, posttransplantmonitoring of disease status
is assured by 2 different methodologies: specific MRD
detection and characterization of chimerism. The last
characterizes the origin of posttransplant hematopoie-
sis, whereas MRD detection measures the malignant
clone directly. For each approach, a variety of tech-
niques are available, although in general there have
beenmore studies lookingdirectly atmarkers of residual
malignancy than at chimerism. Issues of applicability,
standardization, sensitivity, and specificity are discussed
separately for each technique in detail in part I [1].DISEASE-SPECIFIC DEFINITIONS AND
MONITORING OF RELAPSE AFTER
ALLOHSCT
Standard diagnostic criteria have been established
to define response and relapse for the hematologic
Table 1. Diagnostic Methods to Monitor Residual Disease and Relapse of Hematologic Malignancies after alloHSCT
Tumor Marker Detection Chimerism
Method
Chromosomal
Banding FISH
Flow
Cytometry
Antigen
Receptor PCR
Translocation
or Other RT-PCR XY FISH qPCR/STR-PCR
Applicability Subset of
all types
Subset of
all types
ALL; most AML;
CLL; myeloma
ALL; lymphoma;
CLL
CML; Subset of ALL;
subset of AML;
subset of lymphoma
Sex mismatched
alloHSCT
All types with
differences in
donor/recipient
polymorphisms
Sensitivity 1021 1022 1023-1024 1024-1025 1023-1026 1022 1023-1026
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leuke-
mia; FISH, fluorescence in situ hybridization; PCR, polymerase chain reaction; qPCR, quantitative real-time PCR; RT-PCR, reverse transcription PCR;
STR, short tandem repeats.
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based on morphologic BM investigations (eg, blast
count in acute leukemias), imaging methods (eg, occur-
rence of new lymph nodes on fluorodeoxyglucose
(FDG)-positron emission tomography (PET) scans
for non-Hodgkin lymphoma [NHL]), and/or specific
laboratory findings (eg, increased paraprotein by immu-
nofixation and electrophoresis in multiple myeloma
[MM]).Recently,more sensitivemethods have beenuti-
lized to assess patients for disease response. Some, but
not all, of these approaches have been integrated into
response criteria definitions for various hematologic
malignancies. Herein, we propose criteria for incorpo-
ration of currently available methodologies in the defi-
nitions for disease response, persistence, progression,
relapse, and the prediction of relapse after alloHSCT.Table 2. RemissionDefinitions forChronicMyeloid Leukemia
Complete Molecular Remission
Using a quantitative real-time PCR (qPCR) method, the BCR-ABL1 fusion
mRNA is not detectable in the peripheral blood and/or the bone marrow,
by an assay with a sensitivity to allow detection of 1 Ph+ cell in 105 to 106
normal cells. The results should be confirmed by 2 consecutive tests done
at least 4 weeks apart. The duration of molecular remission is defined as
the time from the first negative RT-PCR assay.
A “nested” PCR assay should be used for confirmation of a negative RT-PCR
if the sensitivity of the qPCR is <1025.
Complete Cytogenetic Remission (must be confirmed by a second
assay).
It should be measured using conventional cytogenetic analysis or
hypermetaphase FISH. The definition of complete cytogenetic remission
requires 0% Ph+ metaphases. A minimum of 20 analyzable metaphases
must be assessed for appropriate evaluation of a cytogenetic remission.
Remission should be confirmed with a repeated cytogenetic analysis
within 4 to 12 weeks. The duration of cytogenetic remission is defined as
the time from first negative assay.
Complete Hematologic Remission (must be confirmed by
a second assay).
All of the following:
- WBC <10  109/L;
- Hemoglobin >11 g/dL;
- Platelets <450  109/L;
- Normal WBC differential (<1% precursor cells);
- No disease-related symptoms;
- No palpable splenomegaly;
- No extramedullary disease;
- Normalization of the bone marrow appearance.
PCR indicates polymerase chain reaction; FISH, fluorescence in situ
hybridization; Ph+, Philadelphia chromosome positive; qPCR, quantitative
real-time PCR; RT-PCR, reverse transcription PCR.CML
Remission definitions for CML after alloHSCT
are well defined (Table 2). Relapse constitutes the
main cause of failure after alloHSCT [5], occurring
in 10%-25% of patients transplanted in chronic phase
and up to 70% in patients transplanted in blast phase
[6]. The incidence of relapse has remained relatively
stable over the years, although the negative impact of
relapse on survival has been declining, suggesting an
improved management of relapse over time [6].
Although the Philadelphia chromosome is usually
not seen in cytogenetic analysis patients following
alloHSCT, this does not exclude the presence of residual
leukemic cells. Usually, relapse of CML after alloHSCT
is a slow gradual process, although sudden growth
of CML cells is not uncommon, especially in patients
reaching alloHSCT in advanced phases [7,8]. Relapse
characteristically is first detectable only by using molec-
ular methods indicating a low level of residual disease
[9,10]. Subsequently, it can be detected using cytogen-
etic analysis, FISH, or conventional blood analyzers.
Relapse of CML can occur in chronic, accelerated, or
blast phase following a pattern of progression similar to
newly diagnosed CML (Table 3), although the interval
between phases may be shorter [7,8,11].Qualitative reverse-transcription polymerase
chain reaction (RT-PCR)
It is now well established that the detection of the
chimeric BCR-ABL1mRNA transcript by RT-PCR is a
powerful predictor of subsequent relapse [9,10,12,13].
Several studies had attempted to assess the clinical
significance and predictive value of detecting BCR-
ABL1 transcripts by RT-PCR assay after alloHSCT.
However, the majority of the early studies were based
on qualitative RT-PCR, and the results had been con-
flicting [14-18].
Using a nested primer technique Roth et al. [16]
analyzed 64 CML patients after alloHSCT and
detected BCR-ABL1 transcripts at 1 time point in 37
patients. They concluded that nested RT-PCR could
Table 3. Definition of Relapse in CML
Molecular Relapse (The date of molecular relapse is the date of the first positive RT-PCR assay).†
Is said to be present in a CML patient lacking any other evidence of the disease (ie, patient in hematologic remission and cytogenetic remission) at least 4 months
after alloHSCTwhen any of the following apply:
 Three samples over a minimum of 4 weeks show a BCR-ABL1/ABL1 ratio higher than 0.02% as measured by qPCR tests.*
 Three samples over a minimum of 4 weeks show clearly rising levels of BCR-ABL1/ABL1 ratio with the last 2 higher than 0.02% as measured by qPCR tests.*
 Two samples over a minimum of 4 weeks show a BCR-ABL1/ABL1 ratio higher than 0.05% as measured by qPCR tests.*
Cytogenetic Relapse
Any of the following in a patient lacking any clinical or hematologic evidence of the disease (ie, patient in hematologic remission):
 Presence of 1 or more Ph+ metaphases with standard cytogenetic analysis or hypermetaphase FISH.
 >2% cells with the BCR-ABL1 fusion gene by interphase FISH.
Hematologic Relapse
All of the following:
 Abnormal blood or marrow counts or morphology consistent with CML.
 Cytogenetic and/or molecular confirmation of the presence of the disease.
Hematologic relapse is subclassified into chronic phase, accelerated phase, or blast phase according to following WHO criteria:
 Chronic Phase: None of the features of accelerated phase or blast crisis.
 Accelerated Phase: Any of the following:
 Blasts 10%-19% of WBCs in peripheral blood and/or nucleated bone marrow cells.
 Peripheral blood basophils $20%.
 Persistent thrombocytopenia (<100  109/L) unrelated to therapy.
 Persistent thrombocytosis (>1000  109/L) unresponsive to therapy.
 Increasing spleen size and increasing WBC count unresponsive to therapy.
 Cytogenetic evidence of clonal evolution.‡
 Blast Phase: Any of the following:
 Blasts $20% of peripheral blood white cells or of nucleated bone marrow cells.
 Extramedullary blast proliferation.
 Large foci or clusters of blasts in the bone marrow biopsy.
Progression
The definition of progression of CML is based upon the above definitions of relapse. Once the CML has fulfilled the criteria for relapse at any level (molecular,
cytogenetic, or hematologic), the patient remains at risk of developing disease progression.
Disease progression can thus be defined as any of the following:
 Molecular relapse progressing into cytogenetic or hematologic relapse.
 Cytogenetic relapse progressing into hematologic relapse.
 Hematologic relapse progressing from chronic phase to accelerated phase.
 Hematologic relapse progressing from chronic phase to blast phase.
 Hematologic relapse progressing from accelerated phase to blast phase.
CML indicates chronic myelogenous leukemia; FISH, fluorescence in situ hybridization; PCR, polymerase chain reaction; qPCR, quantitative real-time
PCR; RT-PCR, reverse transcription PCR; alloHSCT, allogeneic hematopoietic stem cell transplantation.
*Other control genes such as BCR, GUS, and G6PDH have been used in several laboratories. No published data exists regarding the use of these control
genes although the same cutoff for the BCR-ABL1/control gene ratio could be applied.
†RT-PCR assays referred to in this table were not done according to the International Scale.
‡Clonal evolution refers to the appearence of new chromosomal abnormailities not previously detected.
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remission (CR) but with an increased risk of disease re-
currence. The Hammersmith group showed that RT-
PCR positivity within 6 months after transplantation
did not predict a worse outcome, whereas RT-PCR
positivity later than 6 months after transplantation
did [17]. Radich et al. [9] presented a comprehensive
multivariate analysis of 346 patients after alloHSCT;
they identified RT-PCR-positivity at 6 to 12 months
post-alloHSCT as 1 independent variable influencing
subsequent relapse. The significance of the presence of
BCR-ABL1 transcripts in predicting disease recurrence
was, however, lost in patients who tested positive more
than 36 months post-alloHSCT [9].
Quantitative RT-PCR
The clinical value of monitoring MRD has been
greatly improved by the use of quantitative PCR
(qPCR) and the establishment of consensus thresholds
of residual disease above which a patient is likely to re-
lapse [19-23]. Serial qPCR techniques can distinguish
those PCR positive patients who have low orfalling BCR-ABL1 levels from those whose levels are
increasing [17]. Patients destined not to relapse after
alloHSCT have persistently undetectable, low, or fall-
ing BCR-ABL1 levels on sequential analysis. After 6 to
12 months, BCR-ABL1 transcripts are usually unde-
tectable and remain so indefinitely. In contrast, in-
creasing or persistently high levels of BCR-ABL1
mRNA precede relapse, often several months before
the cytogenetic detection of the Philadelphia chromo-
some positive BM metaphases. Provided assays are
performed with sufficient frequency; rising or persis-
tently high numbers of BCR-ABL1 transcripts can be
detected prior to frank relapse, and this information
may be used for early therapeutic intervention. Several
studies have demonstrated that the molecular burden
of BCR-ABL1 transcripts, and the kinetics of increas-
ing BCR-ABL1, predict relapse. Lin et al. [17] demon-
strated that the kinetics of BCR-ABL1 level over time
described both impending relapse and response to do-
nor lymphocyte infusion (DLI). Low (or no) residual
BCR-ABL1 was associated with a very low risk of re-
lapse (1%), compared to 75% relapse rate in patients
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Olavarria et al. [10] studied 138 CML patients “early”
(3-5 months) posttransplant and showed that the BCR-
ABL1 level was highly correlated with relapse. Patients
with no evidence of BCR-ABL1 had a 9% risk of sub-
sequent relapse, whereas patients defined as having
a “low” burden of disease or “high” level of transcripts
had a cumulative relapse rate of 30% and 74%, respec-
tively. These results are consistent with a study of 379
CML patients “late” (.18months) posttransplant per-
formed by Radich et al. [24]. Ninety patients (24%) had
at least 1 assay positive for BCR-ABL1, and 13 of 90
(14%) patients relapsed. Only 3 of 289 patients who
were persistently BCR-ABL1 negative relapsed [24].
The highest risk of relapse associated with BCR-
ABL1 MRD appears to be associated with “early”
(#12months) detection after transplant; however, there
may be a need for life-long monitoring. The Hammer-
smith group analyzed 243 patients who had BCR-ABL1
transcripts monitored by qPCR after alloHSCT for
a median of 84.3 months [11]. Patients were allocated
to 1 of 4 categories: (1) 36 patients were “persistently
negative” or had a single low-level positive result;
(2) 51 patients, “fluctuating positive, low level,” had
more than 1 positive result but never more than 2 con-
secutive positive results; (3) 27 patients, “persistently
positive, low level,” had persisting low levels of BCR-
ABL1 transcripts but never more than 3 consecutive
positive results (therefore, never fulfilled the definition
for molecular relapse); and (4) 129 patients relapsed. In
107 of these, relapse was based initially only on molec-
ular criteria; in 72 (67.3%) patients, the leukemia pro-
gressed to cytogenetic or hematologic relapse either
prior to or during treatment with DLI. Their conclu-
sions were that the pattern of BCR-ABL1 transcript
levels after allograft is variable; that only a minority of
patients who had fluctuating or persistent low levels of
BCR-ABL1 transcripts long term eventually relapsed
and that the majority of patients who had a molecular
relapse were likely to progress further [11].
Moreover, occasional CML patients who were
treated by alloHSCT in chronic phase have relapsed
more than 10 years after an otherwise “successful” trans-
plantation [25], and data collated by the CIBMTR show
that the cumulative incidence of relapse at 15 years for
patients in remission at 5 years after alloHSCT was
17% [11,26].
Cytogenetic analysis and FISH
The role of conventional cytogenetic analysis
(ie, G-banding) and FISH in the monitoring of
patients with CML undergoing alloHSCT is
relatively limited [7,27]. These techniques are
necessary for the characterization of the stage of the
relapse and confirmation that the morphologic
changes observed in the PB and/or BM correspond to
CML. Patients who fulfill the criteria for molecularrelapse (Table 3), must have an assay to confirm or
exclude the presence of the Philadelphia chromosome.
This could be FISH in PB/BM or conventional
cytogenetic analysis of BM aspirates. In addition, con-
ventional cytogenetic analysis is necessary to assess the
progression to accelerated phase (ie, presence of clonal
evolution), and FISH analyses may be useful in assess-
ing chimerism status in sex mismatched alloHSCT.
Chimerism studies
There is scant information regarding the use of
chimerism studies in the monitoring of CML patients
after alloHSCT. It is widely accepted that in CML,
relapse occurs in the context of mixed or decreasing
T cell chimerism, and given the hematopoietic poten-
tial of CML cells, this is also true for myeloid
chimerism [28,29]. However, relapses have been
described in the presence of 100% donor chimerism
[30,31]. Chimerism studies could be of some value in
predicting the response to the treatment of relapse
(especially after DLI) and in monitoring the response
to DLI or tyrosine kinase inhibitors (TKIs). Less than
10% donor chimerism predicts for lack of response to
DLI [32]. Achievement of 100% donor chimerism
may be associated with long-term remission [27,33].
However, there is a need to investigate this field
further in future studies.
Application of MRD studies
in prospective CML trials
It is now well established that PCR-based moni-
toring methods play a significant role in the manage-
ment of CML patients undergoing alloHSCT. qPCR
allows for the detection of molecular relapse and accu-
rately predicts for disease progression. Future clinical
trials should evaluate the role of MRD monitoring in
patients reaching the transplant after failure to respond
to the new TKIs. In this context, clinical trials are
needed to determine the value of qPCR in conjunction
with the use of first- or second- generation TKIs either
in a prophylactic or preemptive fashion. Furthermore,
prospective clinical trials should address the potential
synergistic combination of the graft-versus-leukemia
(GVL)/tumor effect of DLI and TKIs in relapsed CML.
Finally, there is a need to validate all the RT-PCR
results mentioned in the previous paragraphs in the
era of standardization of the RT-PCR assays and
the development of an International Scale [34].Myeloproliferative Neoplasms
This section on myeloproliferative neoplasms
(MPNs; a.k.a myeloproliferative disorders) will focus
only on myelofibrosis (primary myelofibrosis [PMF]
or myelofibrosis after either polycythemia vera [PV]
or essential thrombocythemia [ET]), because allo-
HSCT is rarely indicated in uncomplicated PV or
Table 4. IWG-MRT Complete Remission and Progression
Criteria for Myelofibrosis [35]
Complete Remission (CR): requires all of the following:
 Complete resolution of disease-related symptoms and signs including
palpable hepatosplenomegaly.
 Peripheral blood count remission defined as hemoglobin level of at least
11 g/dL, platelet count of at least 100  109/L, and absolute neutrophil
count of at least 1.0  109/L. In addition, all 3 blood counts should be no
higher than the upper normal limit.
 Normal leukocyte differential including disappearance of nucleated red
blood cells, and immature myeloid cells in peripheral smear in the absence
of splenectomy.
 Bone marrow histologic remission defined as the presence of age-adjusted
normocellularity, no more than 5%myeloblasts, and an osteomyelofibrosis
grade no higher than 1.
Complete Cytogenetic Response: CR with failure to detect
a preexisting cytogenetic abnormality.
Major Molecular Response: CR with absence of a previously detected
specific disease-associated mutation in peripheral blood granulocytes.
Partial Remission (PR): requires all of the above criteria for CR except
the requirement for bone marrow histologic remission. However, a repeat
bone marrow biopsy that does not fulfill the criteria for CR is required.
Progressive Disease: requires 1 of the following:
 Progressive splenomegaly that is defined by the appearance of a previous
absent splenomegaly that is palpable at greater than 5 cm below the left
costal margin or a minimum of 100% increase in palpable distance for
baseline splenomegaly of 5-10 cm or a minimum of 50% increase in
palpable distance for baseline splenomegaly of >10 cm.
 Leukemic transformation confirmed by bone marrow blast count of at
least 20%.
 Increase in peripheral blood blast percentage of at least 20% that lasts for 8
weeks.
Relapse: Changes from CR to PR or CR/PR to clinical improvement.*
*Clinical improvement is defined as: absence of PD or CR/PR with im-
provement in peripheral blood (hemoglobin, absolute nutrophil count
(ANC), and platelets, as well as 50% reduction of splenomegaly (for de-
tails see [35]).
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have recently been published by the International
Working Group for Myelofibrosis Research and
Treatment (IWG-MRT; Table 4) [35].
Definitions of remission and relapse for
myelofibrosis after alloHSCT
There is no approved definition of relapse after
alloHSCT for myelofibrosis patients. Based on the
recent IWG-MRT consensus definitions in PMF, it
may be possible to define remission after alloHSCT,
and therefore persistent disease, relapse, and disease
progression could be subsequently inferred. It is
beyond the scope of this review to discuss in detail the
different MPNs and the new molecular classifications
[36,37]. Until recently, the majority of MPN patients
undergoing alloHSCT had been diagnosed with PMF
or atypical MPN, with very few patients having PV or
ET, and almost none diagnosed on the basis of the
molecular defect [38]. In PMF, the situation is con-
founded by the fact that only 50%-60% of patients
show regression of the BM fibrosis in the early post-
transplant period, making it difficult to define relapse
[39]. Given the slow kinetics of progression of PMF, it
is acceptable to assume that relapse after alloHSCT
would follow a similar pattern to CML, although little
is known about this [40]. Furthermore, there is increas-ing evidence to suggest that in PMF, relapse occurs ini-
tially at the molecular level, followed by progression to
cytogenetic and hematologic relapse, imitating what
happens in CML [41]. Clearance of the JAK2mutation
level in PB after alloHSCT as a time-dependent vari-
able significally predicts clinical relapse [41,42].
Hematological remission and relapse. Hema-
tologic remission requires normalization of the BM
cellularity, blast counts, and degree of fibrosis on a
BM biopsy. According to this last criterion, only 60%
of patients will enter remission within the first 3 months
after reduced-intensity conditioning (RIC) alloHSCT;
the proportion increasing to nearly 90% after 12
months. However, hematologic CR also requires nor-
malization of the PB counts, which in alloHSCT pa-
tients may be influenced by graft-versus-host disease
(GVHD), poor engraftment, infections, drug toxicity,
and other posttransplant complications, thus rendering
these criteria invalid in many patients. In this way, the
diagnosis of hematologic relapse in a patient who had
previously achieved a CR is relatively straightforward.
However, in a patient with persistent (but otherwise
decreasing) fibrosis, the detection of a hematologic
relapse could prove extremely difficult in the absence
of other cytogenetic or molecular markers of disease
relapse.
Cytogenetic remission and relapse. In the mi-
nority of patients with PMF who have karyotypic
abnormalities, cytogenetic CR is defined as the absence
of the preexisting abnormalities at any given time after
treatment, whereas minor cytogenetic response is de-
fined by a reduction of at least 50% in the proportion
of positive cells.Whether these criteria could be applied
in practice to PMF patients after alloHSCT remains
unclear. Cytogenetic relapse is thus defined as the reap-
pearance of the previously known chromosomal abnor-
mality (with or without new abnormalities) in a patient
who was previously in cytogenetic remission.
Molecular remission and relapse. Although
a substantial number of myelofibrosis patients today
are known to have a molecular defect, there are no
clear definitions of molecular remission making the
definition of molecular relapse after alloHSCT an im-
portant area of future research. However, new data
suggest that it should be possible to definemolecular re-
mission in JAK2V617F positive myelofibrois patients
using qPCR in a similar way to CML. JAK2V617F
mutation is found in about 50% of patients with mye-
lofibrosis. Kro¨ger et al. [41] described 17 such patients
who became PCR negative after alloHSCT using
a highly sensitive RT-PCR method. Only 2 patients
subsequently relapsed at the molecular level, 1 of
whom progressed to overt hematologic relapse within
6 weeks. Alchalby et al. [42] showed that rapid clear-
ance of JAK2 level in PB significantly reduced the
risk of relapse after alloHSCT. Steckel et al. [43]
reported 15 JAK2V617F positive PMF patients, 12
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Other molecular markers, such as the MPLW515L/K
mutation, are seen in only 5% of myelofibrosis patients
and a smaller series reported rapid clearance after
alloHSCT [44].
It is proposed that molecular remission could be de-
fined as a negative PCR for the presence of the
JAK2V617Fmutation,with an assayof at least 1023 sen-
sitivity, in the PB and/or the BM of a patient who was
positive for themutation prior to transplant. The results
should be confirmed by 2 consecutive tests done at least
4 weeks apart. The duration of molecular remission
should be defined as the time from the first negative
RT-PCRassay.Molecular relapse could thenbe defined
as 2 consecutive positivePCR tests, at least 4weeks apart
in a patient who had previously achieved molecular re-
mission. It is not possible at present to establish a quan-
titative cutoff belowwhich a patient with a positive PCR
assay should remain in molecular remission.Relapse after alloHSCT for myelofibrosis:
Methods of MRD detection qPCR
As noted before, the activating mutation V617F of
the JAK2 gene is an obvious target for monitoring
MRDinpatientswithPMFafter alloHSCT[45].There
are emerging data suggesting that, similar to BCR-
ABL1 in CML, PCR negativity for JAK2V617F corre-
lateswithprolonged remission and that reappearance of
a detectable JAK2V617F clone is associated with
relapse [41-43,46-49]. Furthermore, quantification of
the tumor burden by qPCR may be a useful technique
to monitor MRD after alloHSCT and guide possible
therapeutic interventions. Kro¨ger et al. [50] showed
that it is possible to use qPCR successfully to guide
DLI in PMF patients. Complete disappearance of the
JAK2V617Fmutationwas achieved in a significant pro-
portion of patients receiving 1 ormoreDLIs. Similar to
what occurs inCML, it would seem thatDLIs aremore
effective if performed at a level of molecular residual
disease. In addition, there is evidence that persistence
of the JAK2V617Fmutationmeasured by qPCR corre-
lates with mixed chimerism after alloHSCT [46,50].
PCR-based assays for the detection of JAK2V617F
lack standardization. In a recent study by Lippert et al.
[51], 16 laboratories performed 11 different assays for
the quantification of JAK2V617F allelic burden. The
results showed great variability among laboratories,
low sensitivity in sequencing techniques, and strongdis-
crepancies with 4 techniques, which could be attributed
to inadequate standards or to differentmodes of expres-
sion of results. After calibration of assays with common
JAK2V617F standards (dilutionsofUKE-1 cells innor-
mal leukocytes) there was good correlation among 4
quantitative Taq-Man allele specific PCR assays, 2 of
which were able to detect levels of 0.2% JAK2V617F.
It is highly desirable that a standardized internationalscale for measuring JAK2V617F transcripts be estab-
lished. Lippert et al. [51] recommended combining
plasmidDNAdilutions, which allowprecise quantifica-
tion of the number of copies of JAK2, with at least 1
well-calibrated genomic DNA sample as an internal
control. Finally, there is no consensus as to whether
PB samples or BM samples are the best samples to ana-
lyze. Some investigators suggest that purified blood
granulocytes are preferable [52].
Quantification of the level of the JAK2V617F
mutation can also be done by methods other than
qPCR. Koren-Michowitz et al. [53] measured levels of
JAK2V617F by mass-spectrometry in 60 patients with
the JAK2V617F mutation undergoing alloHSCT and
found that patients in CR had significantly better
survival.
There are a number of other molecular targets that
may prove useful in monitoring MRD in patients with
MPN. As noted earlier, around 5% of PMF cases have
a mutation in the MPL gene, although the proportion
of patients with the MPLW515 mutation undergoing
alloHSCT may be different. This mutation can be
also used for monitoring molecular disease after
alloHSCT [44]. Given the paucity of data with this
and other mutations, the use of PCR or other methods
to monitor MRD needs to be evaluated further.
Cytogenetic analysis and FISH. The role of
conventional cytogenetic analysis andFISHin themon-
itoring of patients with MPN undergoing alloHSCT is
dependent on the presence of an abnormal karyotype or
other chromosomal abnormalities detectable by FISH
at diagnosis. The frequency ranges from 80% in cases
of progression to acute leukemia, 40% in PMF, and
.5% in molecularly defined MPN [46]. However, the
incidence of chromosomal abnormalities in patients
undergoing alloHSCT might be higher.
In PMF and otherMPN, the need to assess BMhis-
tology makes performance of BM cytogenetic studies
routine inmany centers. There is, however, no consen-
sus on the frequency of these studies after alloHSCT.
In contrast to CML, cytogenetic analysis is not neces-
sary to assess the progression to an accelerated phase
of the disease.
Chimerism studies. There is very limited infor-
mation regarding the use of chimerism studies in the
monitoring of MPN patients after alloHSCT. It
widely accepted that relapse occurs in the context of
mixed or decreasing T cell chimerism, although re-
lapses have been described in the presence of 100%
donor chimerism [54,55]. Chimerism studies could
be of some value in predicting or monitoring the
response to the treatment of relapse (eg, after DLI).Overlapping of MRD Detection Methods
In any given patient, it is likely that some combina-
tion (rather than a single test) of the methods described
Table 5. Relapse Definition for Chronic Lymphocytic Leuke-
mia
Relapse: Progression occurring 6 months or later after having achieved CR
or PR
Progression: iwCLL/NCI-WG criteria for CLL progression (at least 1 must
apply)
 Appearance of any new lesion such as enlarged lymph nodes (>1.5 cm),
splenomegaly, hepatomegaly, or other organ infiltrates;
 Increase of lymphadenopathy by 50% or more in greatest determined
diameter of any previous site, or an increase of 50% or more in the sum of
the product of diameters of multiple nodes;
 Increase in the liver or spleen size by 50% or more or the de novo
appearance of hepatomegaly or splenomegaly;
 Increase in the number of blood lymphocytes by 50% or morewith at least
5/nL B cells;
 Transformation to a more aggressive histology (eg, Richter’s syndrome);
 Occurrence of cytopenia (neutropenia, anemia, or thrombocytopenia)
attributable to CLL.
Complete MRDResponse:Clinical remission in the absence of 1 CLL cell
per 10,000 leukocytes in the peripheral blood or bone marrow.
MRD Relapse: Tumor cell recurrence or increases at the MRD level that
does not exceed 5 B cells/nL in the peripheral blood.
CLL indicates chronic lymphocytic leukemia; MRD, minimal residual dis-
ease; CR, complete remission; PR, partial remission.
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sponse after alloHSCT. The integration of sometimes
discrepant results provides an enormous challenge.
Typically, a PMF patient at 3 to 6 months posttrans-
plant could have persistence of BM fibrosis, signs such
as splenomegaly, and, at the same time, a negative
PCR test for the presence of the JAK2V617F mutation
previously detectable before alloHSCT. Another possi-
ble scenario includes 1 in which PCR-based chimerism
studies show 100% donor chimerism in both the mye-
loid and lymphoid lineages, whereas cytogenetic analy-
sis studies confirm the persistence of a previously noted
chromosomal abnormality. Kro¨ger et al. [41] described
5 patients who had a persistently positive RT-PCR for
JAK2V617F after alloHSCT, of which 4 patients
fulfilled the criteria for hematologic CR of the IWG-
MRT. In the same study, Kro¨ger et al. [41] found
a highly significant inverse correlation between donor
chimerism and JAK2V617F PCR negativity. At the
other extreme, in JAK2V617F negative MPN without
chromosomal abnormalities, chimerism studies may
be the only test on which to base therapeutic decisions
apart from histopathologic review of the BM. These is-
sues constitute an important research field in the
monitoring of MPN patients undergoing alloHSCT
and should be evaluated prospectively.
Applications of MRD Monitoring Methods in
Prospective Clinical Trials for MPN
One of the most challenging hurdles in monitoring
MRD in MPN patients after alloHSCT is the defini-
tion of the different levels of relapse: molecular, cyto-
genetic, and hematologic. Another pitfall is the lack of
standardization of the qPCR methods. Currently
available methods have only a sensitivity of 1%-5%,
which is clearly unsatisfactory for posttransplant mon-
itoring. Highly specific qPCR methods have been de-
veloped and should be made widely available. Future
transplant studies should be ready to address the value
of MRD monitoring using quantitative qPCR in pre-
dicting relapse and disease progression. In addition,
an important goal for those studies should be the eval-
uation of the role of PCR-based MRD monitoring in
guiding the use and evaluation of response to DLI.
Such approaches should be applied to the evaluation
of safety and efficacy of JAK2 tyrosine kinase inhibi-
tors before and after alloHSCT.
Chronic Lymphocytic Leukemia (CLL)
The definitions for relapse or progression of CLL
after alloHSCT have traditionally used clinical and he-
matologic parameters and have been recently updated
by the International Working Group CLL (IWCLL)
(Table 5). The guidelines now also incorporate a
definition of MRD negativity as assessed by MRD
flow or allele specific oligonucleotides (ASO) primerimmunoglobulin heavy chain (IgH) qPCR. The
IWCLL/NCI-Working Group defined MRD nega-
tivity as\1 CLL cell in 10,000 benign leukocytes in
PB or BM [56]. Tumor cell increases at the MRD level
do not constitute clinical CLL progression or relapse
unless they exceed 5 B cells/nL in peripheral blood.
Methods for MRD Detection in CLL
Ideally, an assay formeasurement ofMRDshouldbe
CLL-specific, highly sensitive even in the presence of
a majority of physiological B cells, broadly applicable,
easily standardized between laboratories, and capable of
quantification. During recent years, 2 main approaches
ofMRDassessment inCLLhavebeen followed:flowcy-
tometry, taking advantage of the unique immunopheno-
type of CLL, and PCR-based strategies using the clonal
rearrangement of the hypervariable complementary
determining region 3 (CDR3) of the variable (VH) part
of the IgHgene [57-61].
Consensus PCR
CLL is a clonal disorder ofmatureB cells character-
ized by a clone-specific rearrangement of the IgH
CDR3.With appropriate primers annealing to consen-
sus VH framework regions (FR) and joining regions
(JH), respectively, the CLL clone-specific CDR3 rear-
rangement can be amplified and detected by appropri-
ate methods, such as gene scanning or heteroduplex
analysis [60]. This technique does not rely on sequenc-
ing of the individual CDR3 region and thus has the
advantage of being relatively simple and rapid. Because
it has to detect the clonal tumor product against a poly-
clonal background of normal B cells, however, it is less
sensitive than PCR assays based on allele-specific
primers. Consensus IgH PCR is reported to detect 1
monoclonal B cell in 100-1000 benign leukocytes.
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a particular sample cannot be predicted precisely, as it
depends on both the number of benign B cells in the
sample and the length of the PCR product [58-60].
Another disadvantage of consensus IgH PCR is that it
does not allow quantification of the CLL clone and,
thus, of the MRD level. The specificity and sensitivity
of the approach was somewhat improved using
a combination of Southern blotting and labeled
patient specific probes for detection [62].
Clone-specific PCRdnested
Unlike the bcl2/IgH rearrangement in follicular
lymphomas (FLs) and the bcl1/IgH rearrangement in
mantle cell lymphomas (MCLs), CLL has no hallmark
genetic abnormality that can be used as a universal
PCR marker. Therefore, only primers addressing the
CLL-specific CDR3 rearrangement can be used for
specific amplification of the CLL clone. If such an
allele-specific approach is combined with a first-step
consensus IgH PCR (“nested IgH PCR”), CLL cells
can be detected with a very high sensitivity of up to
1026 provided a sufficient amount of DNA is analyzed
[63]. Limitations of nested IgH PCR include the need
for individual sequencing of the VH gene and the fact
that it is not a quantitative method.
Clone-specific PCR
Quantitative measurement of clone-specific IgH
rearrangement, copy numbers, and thus MRD levels,
can be achieved by qPCR using allele-specific primers
similar to the nested PCR together with consensus JH
or FR consensus backward primers and JH or FR
consensus probes [58,60]. The technique can be used
on stored DNA and data interpretation is now
standardized [64], but qPCR is labor-intensive because
of the need for CDR3 sequencing and individual clone
specific primer design and it is not as sensitive as nested
PCR (1024 to 1025) [58,61,65].
Flow cytometry
Recently, 4-color flow cytometry using the charac-
teristic immunophenotype of CLL cells (MRD flow)
has been introduced as a sensitive and quantitative tool-
for MRD detection in CLL. Appropriate CLL-specific
antibody combinations allow for sensitivities of 1024 to
1025 [57,58,66]. Close quantitative correlation (r 5
0.95) and high qualitative concordance with qPCR for
detection of CLL above 1024 could be demonstrated
by experienced operators, even in the presence of anti-
CD20 antibodies [67]. Although it is less reliable than
qPCR below the 1024 threshold, MRD flow is simple,
fast, and applicable to all sample types and therapeutic
regimens without need for a priori-probe construction
from a sample known to be MRD-positive. Based on
an international standard [66], MRD flow is currentlythe most widely used method for routine MRD assess-
ment in CLL. However, the method requires 20-fold
more total leukocytes to achieve the same sensitivity as
qPCR and requires the availability of fresh samples.
Chimerism analysis
Taken together, both MRD flow and allele-
specific qPCR are excellent assays for MRD quantifi-
cation with high sensitivity and specificity in CLL.
Consequently, any method of nonspecific chimerism
determination offers no advantage, and thus chime-
rism assays do not play a relevant role for MRD
measurement after alloHSCT for CLL. Nevertheless,
chimerism analyses can provide very valuable addi-
tional information on GVL activity and resistance. Al-
though individual cases of sustained MRD negativity
in the absence of complete chimerism can occur [65],
data from the 37 patients of the German CLL Study
Group CLL3X study evaluable for this endpoint sug-
gest that MRD clearance by month 112 is almost
always associated with complete donor chimerism, im-
plying that GVL-mediated MRD clearance is based
on graft-versus-hematopoiesis effects. On the other
hand, in the patients with MRD persistence at 12
months, complete chimerism was frequently achieved,
indicating lack of GVL despite effective graft-versus-
hematopoiesis activity (Dreger et al., unpublished data).
In conclusion, incomplete or decreasing chimerism
after alloHSCT for CLL seems to be a predictor of
an insufficient GVL effect, and vice versa, of a high
relapse risk. Thus, MRD and chimerism assessment
are complementary tools essential for guiding post-
transplant immune modulation in CLL.Applications of MRDMonitoring after alloHSCT
in CLL
Based on the high sensitivity and specificity of the
MRD assays available for CLL, as well as their easy ap-
plicability to PB samples, they have been investigated
for a variety of clinical purposes. MRD is important
as potential marker for early prediction of long-term
treatment outcome, and for guidance of posttransplant
preemptive therapy.
Clinical trials in CLL are hampered by the fact that
because of the general indolent course of the disease it
may take very long until clinical endpoints are reached.
In particular, this limits the ability to rapidly assess the
effectiveness of treatments such as immunochemother-
apy and transplantation. Theoretically, endpoints con-
sidering MRD responses or kinetics may be used to
replace clinical endpoints, such as progression-free
survival (PFS) or overall survival (OS), allowing for
much faster identification of patients with high or low
likelihood of long-term disease control. Moreover, in
potentially curative treatment approaches, such as
alloHSCT, MRD might emerge as a surrogate marker
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an early predictor of cure. Because CLL is susceptible
toGVLeffects and antibody-based immunemodulation
[65,67-73], MRDmonitoring could be used for guiding
preemptive immunomodulating interventions, such as
immunosuppression tapering, DLI, and rituximab
administration. Given the unique possibility of
“real-time” monitoring of GVL efficacy provided
by continuous MRD assessment, MRD measurement
could help to delineate mechanisms of GVL activity
and resistance by correlating MRD responses with
the occurrence of potential effectors of GVL, such as
CLL-specific T cells and allo-reactive T cells [74].Prognostic Value of MRD Kinetics after
AlloHSCT for CLL
The prognosis of CLL is essentially determined by
the clinically relevant endpoints survival and disease
progression/relapse. According to the recently up-
dated NCI-Working Group guidelines [56], progres-
sive disease is defined by at least 1 of the criteria
listed in Table 5. Relapse is defined as CLL progres-
sion occurring 6 months or later after having achieved
CR or partial remission (PR). It is important to stress
that these are purely clinical criteria, that is, tumor
cell increases at the MRD level will not count as
CLL progression or relapse unless they exceed 5 B
cells/nL in the PB.
HSCT was the first treatment modality that far ex-
ceeded the efficacy of conventional therapy, thereby es-
tablishing the need formore sensitive tools for response
assessment. Transplantation is a good model to illus-
trate that the predictive value of MRD assessment is
strongly dependent on the treatment modality actually
used, that is, MRD negativity after autologous HSCT
(autoHSCT) has a prognostic meaning different from
that after alloHSCT. Moreover, lessons learned from
alloHSCT provide evidence that MRD kinetics is
more important than absolute MRD levels.
MRD measurement in CLL was first introduced
by Gribben and coworkers [62] in the context of the
Dana-Farber Cancer Institute CLL transplant pro-
gram. This group used a PCR methodology based on
a consensus primer CDR3 PCR plus a patient-
specific oligonucleotide applied to blood and BM sam-
ples obtained after autoHSCT and alloHSCT. They
found a strong correlation between achievement of
MRD negativity and relapse risk in patients who had
undergone autoHSCT with B cell-depleted BM grafts
or alloHSCT with CD6-depleted BM grafts after
myeloablative (MA) treatment [75].
A number of groups have reported quantitative
MRD assessment following alloHSCT. Ritgen et al.
[76] performed an analysis of MRD kinetics using
qPCR and/orMRDflow in 32 patients who had under-
gone RIC alloHSCT and demonstrated that, in themajority of cases, achievement of MRD negativity
was clearly linked to immune intervention, such as
tapering of immunosuppression (n 5 12) or DLIs
(n 5 6). Four additional patients became MRD-
negative immediately post-alloHSCT, and 3 other pa-
tients who had MRD samples available only from
months 5, 33, and 46 onward were also found to be
MRD-negative. With a median follow-up of 72 (41-
101) months, only 1 clinical relapse was observed in
these 25 patients, whereas 6 of the 7 patients remaining
MRD-positive relapsed. Using a highly sensitive
nested PCR method, Farina et al. [60] found perma-
nentMRD negativity or a “mixed pattern” (not consis-
tently negative, but without significant increase over
time) in 16 of 29 patients (55%) in clinical CR after
RIC alloHSCT for CLL. All 3 patients with mixed
pattern who were tested with qPCR in parallel were
MRD-negative. Only 1 of these 16 patients relapsed
during a follow-up time of 40 (12-85) months, whereas
8 of 13 MRD-positive patients developed clinical
relapse. Four additional patients were always MRD-
positive by nested PCR, but showed decreasing or
stable levels by qPCR. None of these 4 relapsed.
More recently, Khouri et al. and Sorror et al. reported
absent or apparently reduced recurrence in 21 and 14
patients, respectively, who achieved MRD negative
clinical CR after RIC alloHSCT as documented by
polyacrylamide gel electrophoresis-based allele-specific
CDR3 PCR [77,78]. Moreno et al. [79] reported com-
plete MRD clearance or “mixed pattern” (and C. Mor-
eno, personal communication, May 2009) by MRD
flow or qPCR in 9 of 15 patients with CLL (60%) after
MA alloHSCT. At a follow-up of 6-120months, only 1
of these 9 patients had relapsed clinically. Caballero
et al. [80] observed a complete clearance of CLL by
MRD flow in the context of acute or chronic GVHD
(aGVHD, cGVHD) in 6 patients by day 360 subse-
quent to being MRD-positive at day 100.
In summary, MRD assessment after alloHSCT is
predictive for durable freedom from CLL progression
if: (1) MRD levels are below 1024 1 year posttrans-
plant; or (2) show decreasing or stable kinetics within
the quantitative range. Taken together, in all studies
employing quantitative MRD assessment, MRD nega-
tivity 1-year posttransplant was not only predictive for
virtual absence of clinical relapse (except for 2 patients
with extranodal disease recurrence), but also durable
over the whole follow-up in.90% of patients. In con-
clusion, MRDmonitoring after alloHSCT for CLL is
capable of identifying those patients with a very low
risk of disease recurrence. Moreover, the fact that con-
versions or increases of MRD are rarely observed in
those patients who became negative upon immune
modulation strongly suggests that these individuals
have a high probability of permanent CLL control.
Therefore, MRD negativity might represent a surro-
gate marker for cure in this subset.
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MRD-guided preemptive immune modulation
and treatment
As successfully applied in CML [31,81],
posttransplant quantitative MRD monitoring might
be used for preemptive CLL-specific immune inter-
vention or targeted therapy. Although the study by
Ritgen et al. [76] suggests that minimal residual CLL
persisting after alloHSCT can be successfully elimi-
nated by induction of GVL following cyclosporine
tapering or DLI, conclusive results from a prospective
study on posttransplant MRD-guided preemptive
treatment are still lacking. Although the results of
DLI observed in the Ritgen study and those of DLI
given for mixed chimerism in the absence of clinical
disease after T-depleted alloHSCT [82] are promis-
ing, it remains to be shown if preemptive strategies
can indeed improve the overall poor results of thera-
peutic DLI in CLL [82-86].
Mechanisms of GVL onset and resistance
The studies that have employed quantitative MRD
monitoring have demonstrated either correlations
between posttransplant MRD kinetics and activity of
cGVHD [60,76,80], or at least a delayed clearance of
MRD suggestive of GVL [79]. Thus, in the absence
of other variables influencing the tumor load, MRD
kinetics could serve as a “real-time” marker of GVL
efficacy and resistance. Accordingly, a promising re-
search perspective is to perform longitudinal studies
of the donor-derived effector cell compartment to
identify and characterize those cell populations that
emerge upon onset of MRD decrease and/or cGVHD.
This could lead to delineation of the mechanisms re-
sponsible for GVL effects in CLL, thereby opening
the avenue for more specific and less toxic cellular
therapies. In turn, analyses of CLL cells and the com-
position of the donor effector cells during increasing
MRD levels despite ongoing GVHD activity might
lead to better understanding of GVL resistance and
ways to overcome it [76]. MRD flow appears particu-
larly suited to assess those markers expressed on
MRD cells that might be associated with GVL resis-
tance.MRD-Guided Preemptive Intervention
Because more than one-third of patients undergo-
ing RIC alloHSCT for poor-risk CLL will experience
relapse, strategies for improvement of long-term leu-
kemia control are a very important research area. As
noted earlier, a promising but poorly investigated ap-
proach to this end is MRD-guided preemptive CLL-
specific therapy posttransplant. Prospective studies
should be devloped to address the benefit of predefined
MRD-triggered immune modulation. These trialsshould not only focus on nonspecific maneuvers such
as immunosuppression tapering and DLI, but also on
other forms of targeted posttransplant interventions.
For example, rituximab given concomitantly with RIC
or DLI might facilitate control of the CLL clone [73].
This could result not only from direct cytotoxicity of
rituximab to CLL cells but also to modulation of the
GVL activity. Because rituximab is rather poorly effec-
tive in CLL, this approach should be extended to other
antibodies or CLL-specific molecules, such as ofatu-
mumab [87]. An even more powerful way of redirect-
ing donor T cells to residual CLL cells could be
posttransplant administration of bispecific antibody
constructs targeting both B and T cell antigens, such
as blinatumomab [88].
NHL and Hodgkin Lymphoma (HL)
For NHL and HL, physical examination, imaging,
and BM morphology are utilized in the assessment of
response and relapse in accordance with the revised
response criteria by International Harmonization Pro-
ject on Lymphoma (IHPL), which are also applied in
the relapse setting (Table 6) [89].
Detection of Lymphoma Relapse
Physical examination
Frequent physical examinations are performed in
the posttransplant setting with evaluation of lymph-
adenopathy or the presence of masses, or asking about
unusual symptoms. Any finding suggestive of lym-
phoma recurrence would lead to further testing and
imaging.
BM biopsies
BM biopsies are usually performed in patients with
lymphoma at the time of initial evaluation and at re-
lapse. However, if the patient’s BM has always been
uninvolved, it is unlikely to be positive at the restaging
points posttransplant. When performing BMs it is im-
portant to get an adequate specimen, either a 200 core
biopsy or 2 100 core biopsies as recommended by the
IHPL response criteria [89].
Timing of the Evaluations
Most transplant centers repeat the previously pos-
itive tests around day1100, 6 months, and 1 year post-
transplant. Many centers continue to repeat these tests
on at least a yearly basis typically for 5 years posttrans-
plant. The clinical benefit of frequent repeated tests is
unknown.
Imaging Studies
Computed tomography (CT), magnetic resonance
imaging (MRI), andPETare standardmethods to eval-
uate disease extent and response in lymphoma and have
Table 6. Response Criteria for Lymphoma Patients according to Cheson et al. [89]
Response Definition Nodal Masses Spleen, Liver Bone Marrow
CR Disappearance of all
evidence of disease.
(a) FDG-avid or PET positive prior to
therapy; mass of any size
permitted if PET negative.
(b) Variably FDG-avid or PET
negative; regression to normal
size on CT.
Not palpable, nodules disappeared. Infiltrate cleared on repeat
biopsy. If indeterminate
by morphology,
immunohistochemistry
should be negative.
PR Regression of measuable
disease and no new sites.
$50% decrease in SPD of up to 6
largest dominant masses; no
increase in size of other nodes.
(a) FDG-avid or PET positive prior to
therapy; 1 or more PET positive at
previously involved site.
(b) Variably FDG-avid or PET
negative; regression on CT.
$50% decrease in SPD of nodules
(for single nodule in greatest
transverse diameter); no
increase in size of liver
and spleen.
Irrelevant if positive prior
to therapy. Cell type
should be specified.
SD Failure to attain
CR/PR or PD.
(a) FDG-avid or PET positive prior
to therapy; PET positive at prior
sites of disease and no new sites
on CTor PET.
(b) Variably FDG-avid or PET
negative; no change in size of
previous lesions on CT.
Relapsed
disease or PD
Any new lesion or increase
by $50% of previously
involved sites from nadir.
Appearance of a new lesion(s) >1.5
cm in any axis, $50% increase in
SPD of more than 1 node, or$50%
increase in longest diameter of
a previously identified node >1 cm
in short axis.
Lesions PET positive if FDG-avid
lymphoma or PET positive
prior to therapy.
> 50% increase from nadir
in the SPD of any previous
lesions.
New or recurrent
involvement.
CR indicates complete remission; FDG, fluorodeoxyglucose; PET, positron emission tomography; CT, computed tomography; PR, partial remission; SPD,
sum of the product of the diameters; SD, stable disease; PD, progressive disease.
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However,CT,MRI, andPETscans are all known topo-
tentially have false positive and false negative results in
some patients. Examples of false positive CT and MRI
scans include residual lymphadenopathy ormasses asso-
ciated with fibrotic tissue. Such would normally be
negative on a PET scan; therefore, these modalities are
complementary. PET scans may also have false posi-
tives, for example, secondary to infection, inflammation,
thymic recovery, or scans done too soon after therapy.
False negatives can occur, although this is less likely
with PET scans in comparison to CT and MRI.
Confirmation of Results
Confirmation of results with a pathologic biopsy is
necessary to diagnose recurrence of lymphoma based
upon a suspicious scan.
Chimerism
The relationship between disease response and do-
nor chimerism by day 90 after transplantation was
evaluated in FL [90]. Seventeen of 33 patients had
mixed chimerism by day 190, yet all experienced
CR, and there was no additional risk of relapse com-
pared with those patients who had full donor chime-
rism at this time point. This observation suggests
that achievement of early full donor chimerism is nota requirement for disease control in indolent lym-
phoma after T cell-replete transplantation. Also, the
use of DLI for treatment of mixed chimerism should
be avoided, unless a rapid decrease in donor chimerism
of more than 20% is observed. Whether this same
strategy can be applied to other histological types
remains to be determined.Clinical Importance of MRD in Lymphoma
The vast majority of B cell malignancies are charac-
terizedby clonal IgHrearrangements,which could serve
as potential targets for MRD detection using methods
similar to those used in acute lymphoblastic leukemia
(ALL) and CLL. In addition, specific chromosomal
translocationsdetectablebyPCRamplification, particu-
larly t(11;14) and t(14;18) translocations, are present in
specific NHL entities [91]. The t(14;18) translocation
is a major pathogenetic mechanism of FL causing
deregulation of the bcl-2 protooncogene, which induces
prolonged cell survival and inhibitionof apoptosis.The t
(11;14) translocation fuses the bcl-1 locus with the IgH
locus on chromosome 14 and is the characteristic trans-
location for MCL. Remarkably, at (14;18) translocation
is also detectable by PCR at low levels in 10%e25% of
healthy individuals [92]. This fact underlines the neces-
sity of serial qPCR approaches in the setting of clinical
MRD studies.
Table 7. Complete Response and Relapse Criteria for Multi-
ple Myeloma According to the European Group for Blood and
Marrow Transplantation (EBMT) and the International
Working Group (IWG) Blade´, Durie et al. [93, 103]
Complete Remission (CR) requires all of the following:
 Absence of the original monoclonal paraprotein in serum and urine by
immunofixation, maintained for a minimum of 6 weeks. The presence of
oligoclonal bands consistent with oligoclonal immune reconstitution does
not exclude CR.
 <5% plasma cells in a bone marrow aspirate and also on trephine bone
biopsy, if biopsy is performed. If absence of monoclonal protein is
sustained for 6 weeks, it is not necessary to repeat the bone marrow,
except in patients with nonsecretory myeloma where the marrow
examination must be repeated after an interval of at least 6 weeks to
confirm CR.
 No increase in size or number of lytic bone lesions (development of
a compression fracture does not exclude response).
 Disappearance of soft tissue plasmacytomas.
IWG Criteria
Complete Remission (CR)
 Negative immunofixation on the serum and urine
 Disappearance of any soft tissue plasmacytomas.
 #5% plasma cells in bone marrow
Stringent Complete Remission (sCR)
 CR as defined above plus
 Normal free light chain ratio and
 Absence of clonal cells in bone marrow by immunohistochemistry or
immunofluorescence
Relapse
EBMT Criteria requires at least 1 of the following:
 Reappearance of serum or urinary paraprotein on immunofixation or
routine electrophoresis, confirmed by at least one further investigation
and excluding oligoclonal immune reconstitution.
 $5% plasma cells in a bone marrow aspirate or on trephine bone biopsy.
 Development of new lytic bone lesions or soft tissue plasmacytomas or
definite increase in the size of residual bone lesions (development of
a compression fracture does not exclude continued response and may not
indicate progression).
 Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or
2.8 mmol/L) not attributable to any other cause.
IWG Criteria
Relapse from CR requires at least 1 of the following:
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and Treatment of Relapse after Allogeneic HSCTThe recent development of assays for quantitative
molecular MRD assessment has allowed comparison
of the relative impact of different treatment modalities
on tumor load and has provided insights into the kinet-
ics of tumor regrowth in FL and MCL. Indeed, this
impact has been observed within the setting of conven-
tional chemotherapy, monoclonal antibodies, and
autoHSCT.
The significance of MRD in patients with relapsed
FL or MCL has not been fully explored, as the inci-
dence of relapse after non-T cell-depleted transplant
has been relatively low (\15%), at least in patients
who received their transplant during chemosensitive
disease. Survival in patients with diffuse large B cell
lymphoma who relapse after a nonmyeloablative or
RIC alloHSCT is dismal (Khouri, unpublished data).
For this reason, PCR monitoring of MRD might in
theory be helpful to evaluate molecular relapse, which
could allow interventions such as programmed immu-
nomodulation before patients experience clinical or ra-
diographic evidence of disease recurrence, although to
date there are no data to support this. For HL, neither
cytogenetic analysis, nor flow cytometry, nor molecu-
lar testing are helpful for assessing residual disease.
Overall, the clinical impact of MRD detection in
different lymphomas remains to be determined. Al-
though MRD has proven to be an independent prog-
nostic factor in other hematologic malignancies, the
clinical relevance of MRD assessment in lymphoma
is still unclear. Further studies are required to obtain
additional MRD information for these patients in the
setting of alloHSCT. Reappearance of serum or urinary M-protein by immunofixation or
electrophoresis
 $5% plasma cells in a bone marrow.
 Appearance of any other sign of progression (i.e, new lytic bone lesions or
soft tissue plasmacytomas or hypercalcemia).
EBMT indicates European Blood and Marrow Transplant; IWG, Interna-
tional Working Group.Multiple Myeloma (MM)
Disease-specific laboratory parameters and imaging
studies are employed in standard response criteria
definitions forMM (Table 7) [93]. Beside these conven-
tional criteria, cytogenetic analysis (including FISH),
lineage-specific chimerism, flow cytometry, and mo-
lecular methods are more sensitive markers to monitor
residual disease and relapse after hematopoietic
alloHSCT. Furthermore, imagingmethods play an im-
portant role in the detection of extramedulllary disease.
Achievement of CR is a major goal of all therapeu-
tic interventions in treatment of MM. Several studies
suggest that those patients who achieve CR, especially
after high-dose chemotherapy, have longer survival
[94,95]. Compared with other treatment modalities in
MM, alloHSCT induces the highest rate of clinical
CR. The CR rate of alloHSCT after standard MA and
after RIC ranged between 27% and 81% [96-102].
These differences result fromdifferent definitions ofCR.
The most commonly used are the definition proposed
by the European Group for Blood and Marrow
Transplantation (EBMT) and of the International
Working Group (IWG) on MM, which introduceda so called stringent definition of CR (sCR) that has
not yet been validated (Table 7) [93,103].
The incidence of relapse in patients with MM after
alloHSCT is higher than in other hematologic diseases.
One reasonmight be that about 50%of the patients will
not achieveCR (defined as negative immunofixation) af-
ter alloHSCT. Therefore, in those patients, “relapse”
shouldbebetter classified as “progressivedisease” rather
than relapse. But even a substantial percentage of the pa-
tients who achieve CR according to the EBMT-criteria
(Table 7) will relapse, demonstrating the low sensitivity
of immunofixation to detect residual disease. The fol-
lowingmethods canbeused todetect either relapse/pro-
gressive disease or persistence of residual disease after
alloHSCT but these, in general, are not included in the
aforementioned common criteria of relapse or CR: (1)
imaging methods, (2) chimerism: nonlineage-specific or
lineage-specific (plasma cells), (3) cytogenetic analysis/
1338 Biol Blood Marrow Transplant 16:1325-1346, 2010N. Kro¨ger et al.FISH, (4) PCRwith patient-specific primers (IgH rear-
rangements), (5) flow cytometry, (6) BMhistology with
immunohistochemistry, and (7) other methods, such as
free light-chain assay.
Imaging Methods
MM is characterized by the presence of lytic bone
lesions and .80% of the patients develop osteolytic
bone lesions [104]. Beside osteolytic bone lesions
almost 10% ofMMpatients present with diffuse osteo-
penia at diagnosis. The hallmark of myeloma bone dis-
ease is an increased osteoclastic bone resorption and an
exhausted osteoblast function resulting in reduced bone
formation even in patients in CR [105,106]. Therefore,
bone scan offers less information in follow-up of bone
disease in myeloma patients. Imaging methods to
monitor patients with MM should: (1) detect skeletal
complications, (2) determine intramedullary bone dis-
ease, and (3) detect extramedullary disease. Currently,
standardized recommendations for imaging in MM
have not been established for newly diagnosed patients
or for follow-up to determine disease progression [107].
Conventional X-ray
Conventional radiologic skeletal survey that in-
cludes the cervical, thoracic, and lumbar spine, skull,
chest, pelvis, humeri, and femora is still the standard
for newly diagnosed MM patients and is repeated
in progressing or relapsing patients as part of the re-
staging process. Conventional X-ray may also reveal
diffuse osteoporosis. There are a number of major dis-
advantages of conventional radiology: some areas of the
spine are not well visualized; the sensitivity for detec-
tion of osteolytic lesions is rather low; it fails to distin-
guishmyeloma-related osteoporosis fromosteoporosis
because of other causes; and it cannot be used for as-
sessment of response to therapy as lytic bone lesions
do not show “healing” and new fractures do not always
indicate disease progression [106,108].
CT
CT scanning is superior to conventional radiology
with respect to sensitivity and allows detection of small
osteolytic lesions that are not detected by conventional
X-ray. This holds true especially for areas such as the
scapula, ribs, and sternum, which cannot be visualized
accurately by conventional radiology [109]. Further-
more, CT scan has been proven to be superior in esti-
mating fracture risk [110]. CT scan can further depict
the extent of soft tissue masses, which are not detectable
by conventional radiology. A new CT technology, the
multidetector row computed tomography (MDCT),
has been found to be very sensitive in detecting osteo-
lytic lesions less than 5 mm in the spine compared
with MRI and PET [111]. In comparison to conven-
tional radiology, CT scanning is much faster, but theamount of radiation dose delivered to the patient is
up to three times higher [112].
MRI
MRI allows visualization of the medullary cavity,
and therefore, the degree of myeloma cell infiltration
can be assessed [113]. The sensitivity of MRI is higher
than conventional radiology in detecting osteolytic
bone disease. For suspected cord compression MRI
is the technique of choice [114]. MRI can also distin-
guish between malignant compression fractures and
other causes such as osteoporotic fracture.
Different MRI techniques have been developed to
assess BM involvement [115].Themost informative se-
quences are theT1-weighted, theT2-weightedwith fat
suppression, the short time inversion recovery (STIR),
and the gadolinium T1-weighted with fat suppression.
Myeloma lesions usually have low signal intensity on
T1-weighted images and high signal intensity on T2-
weighted and STIR images and enhancement on
gadolinium images [116]. BM involvement can be rec-
ognized by 5MRIpatterns [117]: (1) focal involvement,
(2) diffuse infiltration, (3) combined diffuse and focal
infiltration, (4) “salt and pepper” pattern, and (5) nor-
mal appearance despite plasma cell infiltration. Low
myeloma cell infiltration is usually associated with nor-
malMRI pattern, whereas highmyeloma cell burden is
suspected if there is a diffuse hypointense change on
T1-weighted images, diffuse hyperintensity on T2-
weighted images, and enhancement with gadolinium
injection.
MRI is more sensitive than conventional radiology
in detecting osteolytic lesions in the pelvis (75% versus
46%) and spine (76% versus 42%) [118]. In another
large study, a focal lesion could be detected by MRI
in 52% of the patients with normal skeletal survey
[119]. This advantage was mainly observed for the
spine, pelvis, and sternum, whereas a higher number
of lesions were detected by conventional radiology
for ribs and long bones (humeri and femora) [119]. An-
other advantage of MRI is the detection of solitary
bone plasmacytoma (SBP). MRI was able to detect ab-
normal lesions in 4 of 12 patients with SBP that had
not been detected by conventional radiology [120].
MRI can also be used to assess response to therapy.
CRwas associated with complete resolution of the pre-
ceding BM abnormalities and partial response was
demonstrated by conversion of a diffuse to a focal pat-
tern [120]. MRI might also help to assess remission in
non-secretory myeloma. Focal lesions detected by
MRI were seen in 27 of 30 patients with nonsecretory
myeloma. After treatment, CR by BM examination
occurred in 81%, but MRI-based CR was only seen
in 41% of patients [119]. Furthermore, the number
of focal lesions detected by MRI serves as an indepen-
dent prognostic factor. After intensive chemotherapy,
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which was associated with an improved survival. Re-
lapse after CR was associated with focal lesions by
MRI in 70%, including 26% new focal lesions [119].
Nuclear medicine imaging
Technetium bone scintigraphy is able to detect os-
teolytic bone lesions in up to 60% of myeloma patients,
but its specificity and sensitivity to detect or follow bone
lesions is lower compared to conventional radiography
[121,122], mainly because of the osteoblast dysfunct-
ion in myeloma. To improve the sensitivity 99m
Technetium-labeled hexakis-2-methexyiso-butylisonitrile
(99 mTc-sestamibi or MIBI) was introduced, which
favors accumulation in tissues with high cell density
and mitochondrial activation. MIBI has been shown
to be highly sensitive (92%) and specific (96%) in
MM [123], with localization inside the myeloma
cell infiltrating BM [124]. MIBI can detect soft tis-
sue and skeleton lesions with a higher sensitivity
than conventional radiology [125]. In comparison
to FDG-PET scan, the sensitivity of MIBI is lower
and in comparison to MRI the extent of myeloma
infiltration in BM is underestimated [126]. PET us-
ing FDG cannot detect small osteolytic lesions seen
by conventional radiology [127]. To overcome these
limitations PET and CT can be combined (PET-
CT). Several studies have shown that PET-CT is a re-
liable method to detect osteolytic lesions in MM of at
least 1 cm [128] and can be used to monitor nonsec-
retary myeloma patients as well as patients in CR
without measurable M-component [129]. PET-CT
has been included as an option in the diagnosis and
monitoring of myeloma patients within the NCCN
guidelines (http://www.nccn.org/professional/physi-
ciangls/PDF/myeloma.pdf). Regarding extramedullary
disease, PET-CT is more sensitive than other imaging
modalities, showing in up to 30% additional lesions
in patients who have been diagnosed with solitary plas-
macytoma by MRI [130,131]. Small studies have
demonstrated superiority of PET-CT in comparison
to conventional radiography [132]. 18F-FDG PET-
CT is comparable to MRI in the detection of focal
lesions in the spine and pelvis, but it is superior for an
accurate whole-body evaluation [133], andMRI is supe-
rior to PET-CT in detecting BM involvement [134]. In
summary, new imaging methods allow the detection of
small osteolytic lesions and extramedullary disease. For
monitoring myeloma patients, MRI or CT can be used
for response evaluation of soft tissue masses to therapy
and to monitor patients for relapse during post-
treatment follow-up. The roles of PET-CT and/or
MIBI need to be investigated.
Chimerism
Accurate quantitative analysis of donor-recipient
cell chimerism has been reported to permit detectionof residual disease as well as early relapse after
alloHSCT [28,135]. However, this methodology is
only useful in that regard if the underlying disease
originates at an early hematopoietic stem cell level
such as acute leukemia or CML. In MM, which
originates from a late stage of B cell development, no
correlation between donor chimerism and relapse
could be found [136]. This problem of monitoring re-
lapse by donor chimerism in patients withMM after an
allograft may be overcome by using lineage-specific
chimerism. In a small study, chimerism of plasma cells
was monitored after CD1381 cell enrichment [137]. In
this trial, sequential monitoring of donor plasma cell
chimerism showed that increasing or stable chimerism
was associated with ongoing remission in 93% of the
patients, whereas decreasing donor plasma cell chime-
rism predicted clinical relapse in 5 of 6 patients. By us-
ing qPCR the sensitivity of themethod is 1024 to 1025.
The disadvantage of this method is the lack of specific-
ity. In patients with acute leukemia after alloHSCT it
could be shown that full conversion to complete donor
plasma cell chimerism is delayed in comparison to
other hematopoietic cells. Donor plasma cell chime-
rism was only 98.6% at 6 months and 99.8% at 1
year after transplant, whereas 100% donor T cell chi-
merism was almost always achieved at day 100 after
transplantation [137].
Cytogenetic Analysis and FISH
Conventional cytogenetic analysis in myeloma is
difficult to obtain and to date this method has been re-
ported only after autoHSCT where suppression of ab-
normal karyotype is associated with improved survival
[138]. Because of the low proliferation of malignant
plasma cells, only about 30% of patients with MM
have detectable chromosomal abnormalities [139]. To
resolve the problem of conventional cytogenetic analy-
sis, interphase FISHhas been introduced,which enables
assessment regardless of the proliferation potential. The
most frequent abnormalities are del(13q14), t(4;14), del
17p, and t(14;16),whichhavebeen showntobeprognos-
tically relevant [139-143]. The sensitivity of FISH is
about 1%, but this method has not been used so far to
detect residual disease or relapse. A major disadvantage
is that the known specific abnormality is not detectable
in all myeloma cells within individual cases.
PCR Using Patient-Specific IgH Primers
The most sensitive method is based on clonal
markers derived from the rearrangement of IgH genes,
which have to be generated from each patient at diag-
nosis or relapse. Depending on the number of malig-
nant plasma cells and the pretreatment, these primers
can be generated in 60% to 80% of the patients [144-
146]. Using these patient-specific primers, residual
myeloma cells can be detected byPCRwith a sensitivity
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more often after allogeneic than after autoHSCT. In
patients who achieved clinical CR, 9 of 14 allograft-
patients, but only 2 of 15 autograft-patients entered
molecular remission. It is of interest that molecular re-
mission after allografting occurred in some patients
more than 3 years after transplantation [145].
The importance of achieving molecular remission
for long-term disease freedom has been shown for MA
alloHSCT in a retrospective EBMT study [146]. Us-
ing highly sensitive patient-specific primers tomonitor
residual disease, it could be shown that durable PCR-
negativity after allografting had a cumulative risk of
relapse at 5 years of 0%, in comparison to 33% for
PCR-mixed patients and 100% for patients who never
achieved PCR negativity [146]. More recently, Kro¨ger
et al. investigated posttransplant immunotherapy with
escalating DLI and novel agents (thalidomide, borte-
zomib, and lenalidomide) to target CR in 32 patients
with MM who achieved only PR after alloHSCT. CR
defined either by EBMT criteria, or flow-cytometry,
or either patient-specific IgH or plasma cell chimerism
as defined by qPCR was accomplished in 59%, 63%,
and 50% of patients, respectively. Achievement of
CR resulted in an improved 5-year PFS andOS accord-
ing to EBMT criteria (53% versus 35%; P 5 .03 and
90% versus 62%; P5 .06), flow-cytometry (74% versus
15%; P 5 .001 and 100% versus 52%; P 5 .1), or mo-
lecular methods (84% versus 38%; P5 .001 and 100%
versus 71%; P5 .03) [147]. These findings demonstrate
the clinical relevance of the depths of remission after
allografting for long-term survival in myeloma pa-
tients and that these methods should be implemented
in clinical trials of alloHSCT in MM.
Flow Cytometry
Flow cytometry has become an easily applied
method to detect residual myeloma cells. The Euro-
pean Myeloma Network recommends a minimal panel
including CD19 and CD56. A preferred panel would
also include CD20, CD117, CD28, and CD27. Plasma
cell gating should be based onCD38 versus CD138 ex-
pression [148]. This method can achieve sensitivities of
1024, but it is less sensitive than patient-specific IgH
primers [149,150].
Recent studies have shown that achieving remis-
sion by flow cytometry after autologous or alloHSCT
resulted in improved survival in comparison to patients
who achieved only negative immunofixation [147,151,
152] illustrating the need to include this method for
further definition of remission and relapse.
Free Light Chains and Other Assays
The qualitative assay for free light chains has been
reported to be sensitive and specific for detecting and
monitoring diseases caused by monoclonal gammopa-
thies such as MM [153]. The IWG definition ofstringent CR (Table 7) requires normalization of the
free light chain ratio in serum [103]. More recently,
the IWG also published guidelines for serum free
light-chain analysis in MM and related disorders
[154]. To determine stringent CR it was recommen-
ded to perform a serum-free light-chain assay in all
patients who achieved a CR with negative immunofix-
ation. In 52 patients who achieved CR according to the
EBMT criteria with negative immunofixation for at
least 3 months after alloHSCT, the free light-chain
kappa/lambda ratio was also normal in 51 patients,
which does not support an additional value of free
light-chain ratio to determine the depth of remission
in immunofixation negative patients [155]. However,
this assay may detect CR and relapse earlier than im-
munofixation in serial measurements because of the
short half-life of free light chain compared to intact
immunoglobulin. As evidence of this, 26 patients
with negative imunofixation after alloHSCT were
monitored sequentially by both the serum-free light-
chain assay and immunofixation. The authors ob-
served that normalization of the free light chain ratio
preceded the occurrence of immunofixation negativity
by about 3 months. Furthermore, in 10 patients who
relapsed during follow-up from CR the free light-
chain ratio became abnormal at a median of 90 days
before immunofixation became positive [156]. These
preliminary data suggest that the free light-chain ratio
does not help to determine the depths of remission af-
ter alloHSCT, but is a useful marker for earlier detec-
tion of remission or progression in myeloma patients.
The proposed definition of stringent CR also requires
a normal kappa/lambda ratio in bone marrow by immu-
nohistochemistry, but so far no data on immunohisto-
chemistry as a method to detect MRD are available.
The detection of tumor-specific antigens such as
cancer testis antigens on myeloma cells have raised
the question whether monitoring of cancer testis anti-
gens by PCR is helpful to detect relapse. Few data are
available so far, but the applicability of this approach
will likely be limited by the fact that cancer testis anti-
gens are not expressed in all myelomawithin individual
cases [157].SUMMARY, CONCLUSIONS, AND FUTURE
RESEARCH
Because the intention of alloHSCT is to cure the
underlying hematologic malignancy, and because
there is increasing evidence that minimal disease after
alloHSCT may be eradicated by immunotherapeutic
approaches such as DLI, monitoring of disease is of
great importance. The current definitions of remission
and relapse utilized to evaluate most hematologic
malignancies during upfront therapy lack sufficient
sensitivity for use after alloHSCT. Flow cytometry,
Table 8. Response and Relapse Definitions after AlloHSCTdApplication of Monitoring Methodologies
Disease
Definition of
Complete Remission Definition of Relapse Molecular Markers Cytogenetics Chimerism Imaging Flow Cytometry Other Methods
Multiple
myeloma
1) EBMT
2) IWG
1) EBMT
2) IWG
ASO-primer (IgH) Chromosome banding
analysis, FISH
PCR or VNTR/STR MRI
PET-CT
4-8 color flow Free light chain assay
Applicable All patients All patients 40%-80% subgroups All patients All patients All patients Subgroups
Comment Accepted but less
sensitive.
Accepted but less
sensitive.
Important, but not
included in EBMT
and IWG definition.
May be useful.* Mononuclear cell
donor chimerism
not useful. Lineage-
specific donor
chimerism (CD138+
plasma cells)
predicts relapse.*
Not established, but
useful for
extramedullary
disease.*
More sensitive than
EBMT/IWG in
predicting relapse.*
Proposed by IWG, but
no valid data.*
Lymphoma Cheson criteria Cheson criteria ASO-primer (IgH) for
B-cell NHL
Chromosome
banding
analysis, FISH
PCR or VNTR/STR CT/PET 4-6 color flow
Applicable All patients All Patients Subgroups Subgroups All Patients All Patients Subgroups
Comment Well established
for all lymphomas.
Well established
for all lymphomas.
Bcl-2 for FL.
Bcl-1for about 30% of
MCL.
Clonal TCR
rearrangements for
T-NHL.
t(14;18) for FL.
t(11,14) for MCL.
Monitoring T cell by
PCR useful in NHL.
Role not established
in HD.
Well established in all
lymphomas.
Could be helpful for
FL and MCL.*
CML Hematologic
Cytogenetic
Molecular
Hematologic
Cytogenetic
Molecular
BCR-ABL1 RT-PCR Chromosome banding
analysis, FISH
PCR or VNTR/STR 4-6 color flow
Applicable All patients All patients All patients All patients All patients Not applicable Subgroups
Comment qPCR identifies
relapse risk
groups.
Not as sensitive as
qPCR for MRD
detection.
Only helpful in
identifying aberrant
blasts in advanced
phase disease.
Myelofibrosis IWG-MRT IWG-MRT JAK2/MPL Chromosome banding
analysis, FISH
PCR or VNTR/STR MRI Flow cytometry
Applicable All patients All patients Subgroups Subgroups All patients All patients All patients
Comment Not fully applicable. Not fully applicable. High sensitivity and
predictive for
relapse.*
Not investigated.* Correlates with
molecular marker,
but less specific.*
Correlates with
fibrosis regression.*
Circulating CD34+
cells may be useful.*
CLL IW-CLL/NCI IW-CLL/NCI ASO-primer IGH
qPCR
Chromosome banding
analysis, FISH
PCR or VNTR/STR CT MRD flow
Applicable All patients All patients ˜90% Subgroups All patients All patients >95%
Comment iwCLL definition of
MRD negativity:
MRD <1024 by
qPCR or flow.
Predictive for
sustained remission
if <1024 1 year post-
SCT.
More sensitive than
flow (<1024).
No role in relapse
monitoring.
Complete donor
chimerism usually
prerequisite for
MRD negativity, but
not suitable as MRD
marker.
Only to be used if CR
by clinical methods
or in clinical trials.
Predictive for
sustained remission
if < 1024 1 year
post-alloHSCT.
Equally sensitive and
specific as qPCR
up to1024.
FL indicates follicular lymphoma; flow, multiparameter flow cytometry; MCL, mantle cell lymphoma; MRD, minimal residual disease; NHL, non-Hodgkin lymphoma; qPCR, quantitative real-time PCR; RT-PCR, reverse-
transcription PCR; TCR, T cell receptor; VNTR, variable number tandem repeats; PET, positron emission tomography; CLL, chronic lymphocytic leukemia; CT, computed tomography;MRI,magnetic resonance imaging;
FISH, fluorescence in situ hybridization; EBMT, European Blood and Marrow Transplant; IWG, International Working Group; IWG-MRT, International Working Group for Myelofibrosis Research and Treatment.
*Further studies needed
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
6
:1
3
2
5
-1
3
4
6
,
2
0
1
0
1
3
4
1
N
C
I
First
In
te
rn
a
tio
n
a
l
W
o
rk
sh
o
p
o
n
th
e
B
io
lo
gy,
P
re
ve
n
tio
n
,
a
n
d
T
re
a
tm
e
n
t
o
f
R
e
la
p
se
a
fte
r
A
llo
ge
n
e
ic
H
S
C
T
1342 Biol Blood Marrow Transplant 16:1325-1346, 2010N. Kro¨ger et al.molecular methods, and new imaging modalities have
been investigated in recent years and can substiantially
increase the sensitivity of disease detection to 1024 to
1026. The highest sensitivity and specificity can be
achieved by molecular monitoring of tumor- or
patient-specific markers measured by PCR, but not
all diseases have such targets for monitoring. Flow cy-
tometry, although generally not as sensitive as PCR, is
a valuable and even preferable method in some dis-
eases, but is not suitable in others. Very high sensitivity
can also be achieved by determination of donor chime-
rism, but its specificity regarding detection of relapse is
low and differs substantially among diseases. A higher
specificity might be obtained by lineage-specific donor
chimerism, but there are only a few such studies with
limited number of patients. Table 8 summarizes the
different methods of MRD detection in the monitor-
ing of CML, MPN, CLL, lymphoma, and MM, and
the relative pros and cons of the use of these methods
after alloHSCT.
Critically important is the need for standardization
of the different residual disease techniques. Further
clinical trials to assess the utility of these techniques
in each disease entity are also mandatory. The predic-
tive value of posttransplant MRD and chimerism
remains to be determined across all hematologicmalig-
nancies, and we also do not understand how to exploit
fully the kinetics ofMRD and chimerism in the predic-
tion of clinical relapse. Subsequent studies should eval-
uate the efficacy of MRD- and chimerism-guided
therapeutic interventions designed to prevent overt re-
lapse. Thus, critical objectives for future studies in this
area should include the following:
1. Standardization of measurement of molecular
markers for each hematologicmalignancy for which
alloHSCT is employed.
2. Define the kinetics of molecular remission and mo-
lecular relapse and the optimal frequency of MRD
and chimerism monitoring after alloHSCT.
3. Define the utility of molecular markers in regard to
the natural history of posttransplant relapse, and
incorporate MRD markers in the definition of
response and remission after alloHSCT.
4. Assess the efficacy of interventional strategies based
on changes in MRD and/or chimerism to prevent
clinical relapse.ACKNOWLEDGMENTS
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